FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Edwin DeJesus

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Living Beings

HIV-1

Procedures

Concepts & Ideas

Physiology

Viral Drug Resistance

Co-author Network

Publications

TOP 3
Andrew R Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Hui C Liu; Anthony Mills; Andrew Plummer; Martin S Rhee; Paul E Sax; Javier Szwarcberg; Kirsten L White; David Wohl
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Kathleen E Squires; Douglas Ward; Benjamin Young; Henry H Zhao; Nicholaos C Bellos; Edwin DeJesus; Daniel Murphy; Lisa L Ross; Mark Shaefer
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
Paul E Sax; Javier Szwarcberg; Kirsten White; David Wohl; Kitty Yale; Lijie Zhong; Andrew Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Brian P Kearney; Hui C Liu; Anthony Mills; Erin Quirk
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Edwin DeJesus (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Andrew R Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Hui C Liu; Anthony Mills; Andrew Plummer; Martin S Rhee; Paul E Sax; Javier Szwarcberg; Kirsten L White; David Wohl
A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: analysis of week 96 results.
Journal of acquired immune deficiency syndromes (1999) 2013;63(1):96-100.
2012: Kathleen E Squires; Douglas Ward; Benjamin Young; Henry H Zhao; Nicholaos C Bellos; Edwin DeJesus; Daniel Murphy; Lisa L Ross; Mark Shaefer
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
HIV clinical trials 2012;13(5):233-44.
2012: Paul E Sax; Javier Szwarcberg; Kirsten White; David Wohl; Kitty Yale; Lijie Zhong; Andrew Zolopa; Andrew K Cheng; Calvin Cohen; Edwin DeJesus; Joel E Gallant; Brian P Kearney; Hui C Liu; Anthony Mills; Erin Quirk
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Lancet 2012;379(9835):2439-48.
2012: Edwin DeJesus; Joseph Gathe; Keith Henry; Brian P Kearney; Jean-Michel Molina; Srinivasan Ramanathan; Jürgen K Rockstroh; Javier Szwarcberg; Xuelian Wei; Kirsten White; Kitty Yale; Andrew K Cheng
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
Lancet 2012;379(9835):2429-38.
2011: Daniel J Skiest; Douglas Ward; Kenneth Abriola; David Barker; Paul C Bellman; Nicholaos C Bellos; Calvin Cohen; Amy Colson; Edwin DeJesus; Michael Gottlieb; Anne Habel; Zach Haigney; Chiu Bin Hsiao; Homayoon Khanlou; Karam Mounzer; Bruce Rashbaum; Peter Ruane; Frances Santiago; Jane Garb
Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
HIV clinical trials 2011;12(3):131-40.
2011: Calvin Cohen; Richard Elion; Peter Ruane; David Shamblaw; Edwin DeJesus; Bruce Rashbaum; Steven L Chuck; Kitty Yale; Hui C Liu; David R Warren; Srinivasan Ramanathan; Brian P Kearney
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
AIDS (London, England) 2011;25(6):F7-12.
2010: Calvin Cohen; Edwin DeJesus; Anthony Lamarca; Benjamin Young; Linda Yau; Lisa Patel; Cindy Vavro; Mary Beth Wire; Paul Wannamaker; Mark Shaefer
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
HIV clinical trials 2010;11(5):239-47.
2010: Kathleen E Squires; Benjamin Young; Edwin DeJesus; Nicholaos C Bellos; Daniel Murphy; Henry H Zhao; Lisa G Patel; Lisa L Ross; Paul G Wannamaker; Mark Shaefer
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
AIDS (London, England) 2010;24(13):2019-27.
2010: Richard Elion; Daniel Berger; Gary Richmond; Michael Sension; Edwin DeJesus; Paul Cimoch; Marty St Clair; Linda Yau; Belinda Ha
Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir.
HIV clinical trials 2010;11(3):170-3.
2010: David A Cooper; Jayvant Heera; James Goodrich; Margaret Tawadrous; Michael Saag; Edwin DeJesus; Nathan Clumeck; Sharon Walmsley; Naitee Ting; Eoin Coakley; Jacqueline D Reeves; Gustavo Reyes-Teran; Mike Westby; Elna van der Ryst; Prudence Ive; Lerato Mohapi; Horacio Mingrone; Andrzej Horban; Frances Hackman; John Sullivan; Howard Mayer
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
The Journal of infectious diseases 2010;201(6):803-13.
2010: Kathleen E Squires; Benjamin Young; Edwin DeJesus; Nicholaos C Bellos; Daniel Murphy; Denise H Sutherland-Phillips; Henry H Zhao; Lisa G Patel; Lisa L Ross; Paul G Wannamaker; Mark Shaefer
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
HIV clinical trials 2010;11(2):69-79.
2008: Richard Elion; Edwin DeJesus; Michael Sension; Daniel S. Berger; William Towner; Gary Richmond; Marty St Clair; Linda Yau; Belinda Ha
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study.
HIV clinical trials 2008;9(3):152-63.
2008: José Ramon Arribas; Anton L Pozniak; Joel E Gallant; Edwin DeJesus; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Charles Holmes; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2008;47(1):74-8.
2007: Brian A Boyle; Richard Elion; Calvin J Cohen; Edwin DeJesus; Trevor Hawkins; Graeme J Moyle
Advances in HIV therapeutics: news from the 4th International AIDS Society Conference.
The AIDS reader 2007;17(10):484-90.
2006: Anton L Pozniak; Joel E Gallant; Edwin DeJesus; José Ramon Arribas; Brian Gazzard; Rafael E Campo; Shan-Shan Chen; Damian McColl; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):535-40.
2006: Richard Elion; Calvin Cohen; Edwin DeJesus; Robert R Redfield; Joseph C Gathe; Ricky Hsu; Linda Yau; Lisa Ross; Belinda Ha; Randall E Lanier; Trevor Scott
Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
HIV clinical trials 2006;7(6):324-33.
2006: Peter Ruane; Joseph Lang; Edwin DeJesus; Daniel S. Berger; Robin Dretler; Allan Rodriguez; Douglas J Ward; Michael L Lim; Qiming Liao; Sunila Reddy; Marty St Clair; Tania Vila; Mark Shaefer
Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
HIV clinical trials 2006;7(5):229-36.
2006: Edwin DeJesus; Daniel S. Berger; Martin Markowitz; Calvin Cohen; Trevor Hawkins; Peter Ruane; Richard Elion; Charles Farthing; Lijie Zhong; Andrew K Cheng; Damian McColl; Brian P Kearney
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients.
Journal of acquired immune deficiency syndromes (1999) 2006;43(1):1-5.
2006: Joseph J Eron; Patrick Yeni; Joseph C Gathe; Vicente Estrada; Edwin DeJesus; Schlomo Staszewski; Philip Lackey; Christine Katlama; Benjamin Young; Linda Yau; Denise Sutherland-Phillips; Paul Wannamaker; Cindy Vavro; Lisa Patel; Jane Yeo; Mark Shaefer
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Lancet 2006;368(9534):476-82.
2006: Joseph C Gathe; Robin Wood; Ian Sanne; Edwin DeJesus; Dirk Schürmann; Andrzej Gladysz; Cindy Garris; Naomi Givens; Robert Elston; Jane Yeo
Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Clinical therapeutics 2006;28(5):745-54.
2006: Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Victoria Wirtz; Anna Rightmire; Linda Odeshoo; Colin McLaren
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
AIDS (London, England) 2006;20(5):711-8.
2006: Mike Youle; Schlomo Staszweski; Bonaventura Clotet; José Ramon Arribas; Anders Blaxhult; Giampiero Carosi; Edwin DeJesus; Gianni Di Perri; Vicente Estrada; Martin Fisher; Colin Kovacs; Ranjababu Kulasegaram; Adriano Lazzarin; Debbie Marriott; Leopoldo Muñoz; Jacques Reynes; Peter Shalit; Jihad Slim; Christos M Tsoukas; Anthony Vaccaro; José Vera
Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
HIV clinical trials 2006;7(2):86-96.
2006: Joel E Gallant; Edwin DeJesus; José Ramon Arribas; Anton L Pozniak; Brian Gazzard; Rafael E Campo; Biao Lu; Damian McColl; Steven Chuck; Jeffrey Enejosa; John J Toole; Andrew K Cheng
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
The New England journal of medicine 2006;354(3):251-60.
2005: Nestor Sosa; Christina Hill-Zabala; Edwin DeJesus; Gisela Herrera; Allison Florance; Maria Watson; Cindy Vavro; Mark Shaefer
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):422-7.
2005: Martin Markowitz; Christina Hill-Zabala; Joseph Lang; Edwin DeJesus; Qiming Liao; E Randall Lanier; E Anne Davis; Mark Shaefer
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2005;39(3):257-64.
2005: Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Anna Rightmire; Serap Sankoh; Richard Wilber
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
AIDS (London, England) 2005;19(7):685-94.
2005: Graeme J Moyle; Edwin DeJesus; Pedro Cahn; Steve A Castillo; Henry Zhao; David N Gordon; Charles Craig; Trevor R Scott
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Journal of acquired immune deficiency syndromes (1999) 2005;38(4):417-25.
2005: Margaret Johnson; Beatriz Grinsztejn; Claudia Rodriguez; Jeffrey Coco; Edwin DeJesus; Adriano Lazzarin; Kenneth Lichtenstein; Anna Rightmire; Serap Sankoh; Richard Wilber
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
AIDS (London, England) 2005;19(2):153-62.
2005: Philip Keiser; Michael G Sension; Edwin DeJesus; Allan Rodriguez; Jeffrey F Olliffe; Vanessa C Williams; John H Wakeford; Jerry W Snidow; Anne D Shachoy-Clark; Julie W Fleming; Gary E Pakes; Jaime E Hernandez
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
BMC infectious diseases 2005;5():2.
2004: Edwin DeJesus; Gisela Herrera; Eugenio Teofilo; Jan Gerstoft; Carlos Beltran Buendia; J David Brand; Cindy H Brothers; Jaime Hernandez; Steve A Castillo; Tab Bonny; E Randall Lanier; Trevor R Scott
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(7):1038-46.
2004: Peter Ruane; Edwin DeJesus
New nucleoside/nucleotide backbone options: a review of recent studies.
Journal of acquired immune deficiency syndromes (1999) 2004;37 Suppl 1():S21-9.
2004: Edwin DeJesus; Debra McCarty; Charles Farthing; Denise D Shortino; Beatriz Grinsztejn; Deborah A Thomas; Shannon R Schrader; Steve A Castillo; Michael G Sension; Kevin Gough; Sam J Madison
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(3):411-8.
2004: Joseph C Gathe; Prudence Ive; Robin Wood; Dirk Schürmann; Nicholaos C Bellos; Edwin DeJesus; Andrzej Gladysz; Cindy Garris; Jane Yeo
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
AIDS (London, England) 2004;18(11):1529-37.
2004: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal Muhamad A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
JAMA : the journal of the American Medical Association 2004;292(2):191-201.
2004: Gregory J Dore; David A Cooper; Anton L Pozniak; Edwin DeJesus; Lijie Zhong; Michael D Miller; Biao Lu; Andrew K Cheng
Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
The Journal of infectious diseases 2004;189(7):1185-92.
2004: Peter Ruane; Gary J Richmond; Edwin DeJesus; Christina E Hill-Zabala; Susan C Danehower; Qiming Liao; Judy Johnson; Mark Shaefer
Pharmacodynamic effects of zidovudine 600 mg once/day versus 300 mg twice/day in therapy-naïve patients infected with human immunodeficiency virus.
Pharmacotherapy 2004;24(3):307-12.
2002: Michael G Sension; Nicholaos C Bellos; Judy Johnson; Gladys E Sepulveda; Edwin DeJesus; Jorge L Santana; Michael H Ames; S Diane Goodwin
Lamivudine 300 mg QD versus continued lamivudine 150 mg BID with stavudine and a protease inhibitor in suppressed patients.
HIV clinical trials 2002;3(5):361-70.